Work

Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.4507

Authors: Charlene Mantia, Opeyemi Jegede, Hollis Viray, Michael B. Atkins, Lisa Rosenblatt, Xin Yin, David F. McDermott, Meredith M. Regan

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Bristol-Myers Squibb (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399381367

Cites:

Cited by: 2

Related to: 10